Kish, J. K.
Ward, M. A.
Garofalo, D.
Ahmed, H. V.
McRoy, L.
Laney, J.
Zanotti, G.
Braverman, J.
Yu, H.
Feinberg, B. A.
Funding for this research was provided by:
Pfizer
Article History
Received: 5 May 2017
Accepted: 18 March 2018
First Online: 2 May 2018
Ethics approval and consent to participate
: All patient records were de-identified prior to study cohort selection in accordance with the Health Insurance Portability and Accountability Act (HIPAA) of 1996. A central institutional review board (Western IRB, Puyallup, Washington) reviewed the study protocol and deemed the study exempt from full review. A waiver of informed consent was obtained for the study.
: All authors approved of the manuscript and consented to its publication.
: Hassan Ahmed, Lynn McRoy, and Giovanni Zanotti are employees of Pfizer Inc. Melea Ward was an employee of Pfizer at the time the manuscript was submitted. Jonathan Kish, JaLyna Laney, Hsing-Ting Yu, and Bruce Feinberg are employees of Cardinal Health Specialty Solutions, who were paid contractors to Pfizer in the development of this manuscript. David Garofalo and Julia Braverman were employees of Cardinal Health Specialty Solutions during the conduct of the study and the initiation of the manuscript. This research was performed under a research contract between Cardinal Health Specialty Solutions and Pfizer and was funded by Pfizer.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.